Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 6/2019

07-02-2019

The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C

Auteurs: Diego Alves Vieira, Luciana Rodrigues da Cunha, Cliviany Borges da Silva, Maria Thereza Bastos Almeida, Adriana Dias Gomes, César Lúcio Lopes de Faria Jr., Rosângela Teixeira, Fernando Silva Neves, Gifone Aguiar Rocha, Fabrício Freire de Melo, Dulciene Maria de Magalhães Queiroz, Luciana Diniz Silva

Gepubliceerd in: Quality of Life Research | Uitgave 6/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Chronic hepatitis C (CHC) is associated with a decreased health-related quality of life (HRQOL). More recent studies have pointed toward a genetic basis of patient-reported quality of life outcomes. Taking into account that the influence of single-nucleotide polymorphisms (SNPs) on the HRQOL of CHC patients has not been studied, we investigated the combined IL10-1082G/A, − 819C/T, and − 592C/A SNPs, and IL6-174G/C SNP. We also evaluated the association between demographic, clinical, psychiatric, virological, and genetic variables with domains and summaries of HRQOL in CHC patients.

Methods

132 consecutive CHC patients and 98 controls underwent psychiatric evaluation by using the Mini International Neuropsychiatric Interview. HRQOL was assessed by a generic questionnaire, the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), and by the specific Liver Disease Quality of Life Questionnaire (LDQOL). IL6 and IL10 polymorphisms were evaluated by Taqman SNP genotyping assay. Multivariate analysis was used to evaluate the associations.

Results

Major depressive disorder was associated with lower SF-36 and LDQOL scores in seven and ten domains, respectively. Diabetes and hypertension were also associated with reduced HRQOL. CHC patients carrying the combination of IL10 ATA haplotype/IL6-GG genotype had lower scores in the SF-36—physical functioning domain, and reduced scores in the LDQOL effects of liver disease on activities of daily living, quality of social interaction, and sexual function domains than the non-carriers of the combined haplotype/genotype.

Conclusion

This is the first study to demonstrate that combined IL6 high-producer GG genotype and IL10 low-producer ATA haplotype is associated with poorer HRQOL in CHC patients.
vorige artikel Diversity in changes of HRQoL over a 1-year period after radiotherapy in Norwegian breast cancer patients: results of cluster analyses
volgende artikel A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
2.
Polaris Observatory HCV Collaborators. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatology, 2(3), 161–176.CrossRef
3.
Younossi, Z., Park, H., Henry, L., Adeyemi, A., & Stepanova, M. (2016). Extrahepatic manifestations of hepatitis C: A Meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology, 150, 1599–1608.CrossRefPubMed
4.
Ramos-Casals, M., Zignego, A. L., Ferri, C., Brito-Zerón, P., Retamozo, S., Casato, M., et al. (2017). Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Journal of Hepatology, 66(6), 1282–1299.CrossRefPubMed
5.
el-Serag, H. B., Kunik, M., Richardson, P., & Rabeneck, L. (2002). Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 123, 476–482.CrossRefPubMed
6.
Lee, K., Otgonsuren, M., Younoszai, Z., Mir, H. M., & Younossi, Z. M. (2013). Association of chronic liver disease with depression: A population-based study. Psychosomatics, 54, 52–59.CrossRefPubMed
7.
Silva, L. D., Cunha, C. C., Cunha, L. R., Araújo, R. F., Barcelos, V. M., Menta, P. L., et al. (2015). Depression rather than liver impairment reduces quality of life in patients with hepatitis C. Revista Brasileira de Psiquiatria, 37(1), 21–30.CrossRefPubMed
8.
Dusheiko, G. (2017). The impact of antiviral therapy for hepatitis C on the quality of life: A perspective. Liver International, 37(Suppl. 1), 7–12.CrossRefPubMed
9.
10.
Bakas, T., McLennon, S. M., Carpenter, J. S., Buelow, J. M., Otte, J. L., Hanna, K. M., et al. (2012). Systematic review of health-related quality of life models. Health Quality of Life Outcomes, 10, 134.CrossRefPubMed
11.
Olson, S. H., Iyer, S., Scott, J., Erez, O., Samuel, S., Markovits, T., et al. (2005). Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Quality of Life Outcomes, 3, 39.CrossRefPubMed
12.
Helbling, B., Overbeck, K., Gonvers, J. J., Malinverni, R., Dufour, J. F., Borovicka, J., et al. (2008). Host-rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut, 57, 1597–1603.CrossRefPubMed
13.
Bianchi, G., Marchesini, G., Nicolino, F., Graziani, R., Sgarbi, D., Loguercio, C., et al. (2005). Psychological status and depression in patients with liver cirrhosis. Digestive Liver Disease, 37, 593–600.CrossRefPubMed
14.
Sprangers, M. A., Bartels, M., Veenhoven, R., Baas, F., Martin, N. G., Mosing, M., et al. (2010). Which patient will feel down, which will be happy? The need to study the genetic disposition of emotional states. Quality of Life Research, 19, 1429–1437.CrossRefPubMedPubMedCentral
15.
Hampton, T. (2004). Patients’ genes may influence quality of life before cancer chemotherapy. JAMA, 292, 673–674.CrossRefPubMed
16.
Sprangers, M. A., Thong, M. S., Bartels, M., Barsevick, A., Ordoñana, J., Shi, Q., et al. (2014). Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: An update. Quality of Life Research, 23(7), 1997–2013.CrossRefPubMedPubMedCentral
17.
Rausch, S. M., Clark, M. M., Patten, C., Liu, H., Felten, S., Li, Y., et al. (2010). Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors. Cancer, 116, 4103–4113.CrossRefPubMedPubMedCentral
18.
Alexander, K., Cooper, B., Paul, S. M., West, C., Yates, P., Kober, K. M., et al. (2014). Evidence of associations between cytokine gene polymorphisms and quality of life in patients with cancer and their family caregivers. Oncology Nursing Forum, 41(5), E267–E281.CrossRefPubMed
19.
Schoormans, D., Radonic, T., de Witte, P., Groenink, M., Azim, D., Lutter, R., et al. (2012). Mental quality of life is related to a cytokine genetic pathway. PLoS ONE, 7(9), e45126.CrossRefPubMedPubMedCentral
20.
Alexander, K. E., Cooper, B. A., Paul, S. M., Yates, P., Aouizerat, B. E., & Miaskowski, C. (2016). Phenotypic and molecular characteristics associated with various domains of quality of life in oncology patients and their family caregivers. Quality of Life Research, 25(11), 2853–2868.CrossRefPubMedPubMedCentral
21.
Sghaier, I., Mouelhi, L., Rabia, N. A., Alsaleh, B. R., Ghazoueni, E., Almawi, W. Y., et al. (2017). Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine, 89, 62–67.CrossRefPubMed
22.
Falleti, E., Fabris, C., Vandelli, C., Colletta, C., Cussigh, A., Smirne, C., et al. (2010). Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. Human Immunology, 71(10), 999–1004.CrossRefPubMed
23.
Swiątek, B. J. (2012). Is interleukin-10 gene polymorphism a predictive marker in HCV infection? Cytokine Growth Factor Review, 23, 47–59.CrossRef
24.
Persico, M., Capasso, M., Persico, E., Masarone, M., Renzo, Ad, Spano, D., et al. (2006). Interleukin-10–1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. Journal of Hepatology, 45, 779–785.CrossRefPubMed
25.
Yee, L. J., Tang, J., Gibson, A. W., Kimberly, R., Van Leeuwen, D. J., & Kaslow, R. A. (2001). Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology, 33, 708–712.CrossRefPubMed
26.
Turner, D. M., Williams, D. M., Sankaran, D., Lazarus, M., Sinnott, P. J., & Hutchinson, I. V. (1997). An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics, 24, 1–8.CrossRefPubMed
27.
Eskdale, J., Gallagher, G., Verweij, C. L., Keijsers, V., Westendorp, R. G., & Huizinga, T. W. (1998). Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proceedings of the National Academy of Sciences of the United States of America, 95, 9465–9470.CrossRefPubMedPubMedCentral
28.
Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V., Yudkin, J. S., Humphries, S., et al. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation, 102(7), 1369–1376.CrossRefPubMedPubMedCentral
29.
Woo, P., & Humphries, S. E. (2013). IL-6 polymorphisms: A useful genetic tool for inflammation research? Journal of Clinical Investigation, 123(4), 1413–1414.CrossRefPubMed
30.
Giannitrapani, L., Soresi, M., Balasus, D., Licata, A., & Montalto, G. (2013). Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World Journal of Gastroenterology, 19(16), 2449–2455.CrossRefPubMedPubMedCentral
31.
Falasca, K., Mancino, P., Ucciferri, C., Dalessandro, M., Manzoli, L., Pizzigallo, E., et al. (2009). Quality of life, depression, and cytokine patterns in patients with chronic hepatitis C treated with antiviral therapy. Clinical and Investigative Medicine, 32(3), E212–E218.CrossRefPubMed
32.
Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. Lancet, 383(9930), 1749–1761.CrossRefPubMed
33.
Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24, 289–293.CrossRefPubMed
34.
Child, C. G., & Turcotte, J. G. (1964). Surgery and portal hypertension. Major Problems in Clinical Surgery, 1, 1–85.PubMed
35.
D’Amico, G., Pasta, L., Morabito, A., D’Amico, M., Caltagirone, M., Malizia, G., et al. (2014). Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients. Alimentary Pharmacololgy Therapy, 39, 1180–1193.CrossRef
36.
Amorim, P. (2000). Mini International Neuropsychiatric Interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Revista Brasisleira de Psiquiatria., 22, 106–115.CrossRef
37.
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22–33: quiz 34–57.
38.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (DSM-IV) (4th edn.). Washington, DC: American Psychiatric Association.
39.
Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483.CrossRef
40.
Ware, J. E., Kosinski, M., & Keller, S. K. (1994). SF-36 physical and mental health summary scales: A user’s manual. Boston: New England Medical Center, The Health Institute.
41.
42.
Gralnek, I. M., Hays, R. D., Kilbourne, A., Rosen, H. R., Keeffe, E. B., Artinian, L., et al. (2000). Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease-the LDQOL 1.0. The American Journal of Gastroenterology, 95, 3552–3565.PubMed
43.
Queiroz, D. M. M., Anacleto, C., Trant, C. G., Pinto, A. M., Calixto, R. S., Teixeira, K. N., et al. (2013). Ancestral origin and virulence markers of H. pylori strains and host genetic structure as predictors of gastric cancer and duodenal ulcer in an admixed population. Gastroenterology, 144 (suppl 1), S-4.CrossRef
44.
Campolina, A. G., Bortoluzzo, A. B., Ferraz, M. B., & Ciconelli, R. M. (2011). Validation of the Brazilian version of the generic six-dimensional short form quality of life questionnaire (SF-6D Brazil). Ciência e Saúde Coletiva, 16(7), 3103–3110.CrossRefPubMed
45.
Laguardia, J., Campos, M. R., Travassos, C. M., Najar, A. L., Anjos, L. A., & Vasconcellos, M. M. (2011). Psychometric evaluation of the SF-36 (v.2) questionnaire in a probability sample of Brazilian households: Results of the survey Pesquisa Dimensões Sociais das Desigualdades (PDSD), Brazil, 2008. Health Quality of Life Outcomes, 9, 61.CrossRefPubMed
46.
Laguardia, J., Campos, M. R., Travassos, C., Najar, A. L., Anjos, L. A., & Vasconcellos, M. M. (2013). Brazilian normative data for the Short Form 36 questionnaire, version 2. Revista Brasileira de Epidemiologia, 16(4), 889–897.CrossRefPubMed
47.
de Dias Teixeira, M. C., M., & Strauss, E. (2005). Fátima Gomes de Sá Ribeiro. A new insight into the differences among non-cirrhotic and cirrhotic patients using the liver disease quality of life instrument (LDQOL). Annals of Hepatology, 4, 264–271.CrossRef
48.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences. New York: Routledge.
49.
Hussain, K. B., Fontana, R. J., Moyer, C. A., Su, G. L., Sneed- Pee, N., & Lok, A. S. (2001). Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. The American Journal of Gastroenterology, 96, 2737–2744.CrossRefPubMed
50.
Fontana, R. J., Moyer, C. A., Sonnad, S., et al. (2001). Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. The American Journal of Gastroenterology, 96, 170–178.CrossRefPubMed
51.
Lim, J. K., Cronkite, R., Goldstein, M. K., & Cheung, R. C. (2006). The impact of chronic hepatitis C and comorbid psychiatric illnesses on health-related quality of life. Journal of Clinical Gastroenterology, 40, 528–534.CrossRefPubMed
52.
Kwan, J. W., Cronkite, R. C., Yiu, A., Goldstein, M. K., Kazis, L., & Cheung, R. C. (2008). The impact of chronic hepatitis C and co-morbid illnesses on health-related quality of life. Quality of Life Research, 17(5), 715–724.CrossRefPubMed
53.
Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45, 295–300.CrossRefPubMedPubMedCentral
54.
Mehta, G., & Dusheiko, G. (2015). Hepatitis C treatment and quality of life—You can’t always get what you want, but you might get what you need. Journal of Hepatology, 63(2), 300–302.CrossRefPubMed
55.
Sprangers, M. A. G., Sloan, J. A., Barsevick, A., Chauhan, C., Dueck, A. C., Raat, H., et al. (2010). Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Quality of Life Research, 19, 1395–1403.CrossRefPubMedPubMedCentral
56.
Saligan, L. N., & Kim, H. S. (2012). A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain, Behavior, and Immunity, 26(6), 830–848.CrossRefPubMedPubMedCentral
57.
Aouizerat, B. E., Dodd, M., Lee, K., West, C., Paul, S. M., Cooper, B. A., et al. (2009). Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biological Research for Nursing, 11(1), 27–41.CrossRefPubMed
58.
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., et al. (2010). A meta-analysis of cytokines in major depression. Biological Psychiatry, 67, 446–457.CrossRefPubMed
59.
Illi, J., Miaskowski, C., Cooper, B., Levine, J. D., Dunn, L., West, C., et al. (2012). Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine, 58, 437–447.CrossRefPubMedPubMedCentral
60.
da Rocha, N. S., Power, M. J., Bushnell, D. M., & Fleck, M. P. (2009). Is there a measurement overlap between depressive symptoms and quality of life? Comprehensive Psychiatry, 50(6), 549–555.CrossRefPubMed
61.
Eren, I., Erdi, O., & Sahin, M. (2008). The effect of depression on quality of life of patients with type II diabetes mellitus. Depress Anxiety, 25(2), 98–106.CrossRefPubMed
62.
Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E. Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7(1), 39–55.CrossRefPubMed
63.
Trevisol, D. J., Moreira, L. B., Fuchs, F. D., & Fuchs, S. C. (2012). Health-related quality of life is worse in individuals with hypertension under drug treatment: Results of population-based study. Journal of Human Hypertension., 26(6), 374–380.CrossRefPubMed
64.
Rutte, A., van Splunter, M. M., van der Heijden, A. A., Welschen, L. M., Elders, P. J., Dekker, J. M., et al. (2015). Prevalence and correlates of sexual dysfunction in men and women with type 2 diabetes. Journal of Sex Marital Therapy, 41(6), 680–690.CrossRefPubMed
65.
Shivananda, M. J., & Rao, T. S. (2016). Sexual dysfunction in medical practice. Current Opinion in Psychiatry, 29(6), 331–335.CrossRefPubMed
66.
Foster, G. R. (2009). Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis, 16(9), 605–611.CrossRefPubMed
67.
Marchesini, G., Bianchi, G., Amodio, P., Salerno, F., Merli, M., Panella, C., et al. (2001). Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology, 120(1), 170–178.CrossRefPubMed
68.
Hsu, P. C., Krajden, M., Yoshida, E. M., Anderson, F. H., Tomlinson, G. A., & Krahn, M. D. (2009). Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver International, 29(3), 449–458.CrossRefPubMed
69.
Durazzo, M., Premoli, A., Di Bisceglie, C., Bo, S., Ghigo, E., & Manieri, C. (2010). Male sexual disturbances in liver diseases: What do we know? Journal of Endocrinological Investigation, 33(7), 501–505.CrossRefPubMed
Metagegevens
Titel
The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C
Auteurs
Diego Alves Vieira
Luciana Rodrigues da Cunha
Cliviany Borges da Silva
Maria Thereza Bastos Almeida
Adriana Dias Gomes
César Lúcio Lopes de Faria Jr.
Rosângela Teixeira
Fernando Silva Neves
Gifone Aguiar Rocha
Fabrício Freire de Melo
Dulciene Maria de Magalhães Queiroz
Luciana Diniz Silva
Publicatiedatum
07-02-2019
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02129-5

Andere artikelen Uitgave 6/2019

Quality of Life Research 6/2019 Naar de uitgave

Review

Health-related quality of life among adults living with diabetic foot ulcers: a meta-analysis

Correction

Correction to: The impact of caregiver’s role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver’s disclosure of terminal disease status

OriginalPaper

Nonrestorative sleep scale: reliable and valid for the Chinese population

OriginalPaper

Psychometric properties and correlates of a brief scale measuring the psychological construct mattering to others in a sample of women recovering from breast cancer

OriginalPaper

The effects of clinical illness severity and physical activity on health-related quality of life in schizophrenia

OriginalPaper

Development and validation of the caregiver roles and responsibilities scale in cancer caregivers